

Faina Nakhlis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9456278/publications.pdf>

Version: 2024-02-01

36
papers

453
citations

759233

12
h-index

713466

21
g-index

37
all docs

37
docs citations

37
times ranked

497
citing authors

#	ARTICLE	IF	CITATIONS
1	Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1660-1667.	1.5	14
2	ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1668-1669.	1.5	0
3	How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 3764-3771.	1.5	6
4	Abstract P2-12-18: A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer. <i>Cancer Research</i> , 2022, 82, P2-12-18-P2-12-18.	0.9	1
5	ASO Visual Abstract: How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective Consecutive Patient Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
6	Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. <i>Annals of Surgical Oncology</i> , 2022, 29, 7696-7702.	1.5	2
7	Inflammatory Breast Cancer: Is There a Role for Deescalation of Surgery?. <i>Annals of Surgical Oncology</i> , 2022, 29, 6106-6113.	1.5	7
8	The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034). <i>Annals of Surgical Oncology</i> , 2021, 28, 2573-2578.	1.5	27
9	Abstract PD4-06: How often does retrieval of a clipped lymph node change adjuvant therapy recommendations? A prospective consecutive patient cohort. , 2021, , .		1
10	Abstract PS14-21: Refining loco-regional therapy for inflammatory breast cancer protocol in progress. , 2021, , .		0
11	Abstract PS14-09: The impact of non-classic LCIS on the natural history of DCIS. , 2021, , .		0
12	MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. <i>Academic Radiology</i> , 2021, , .	2.5	1
13	Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. <i>Breast Journal</i> , 2020, 26, 384-390.	1.0	10
14	Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERBB3 alterations. <i>Modern Pathology</i> , 2020, 33, 1287-1297.	5.5	19
15	Impact of surgical complications on patient reported outcomes (PROs) following nipple sparing mastectomy. <i>American Journal of Surgery</i> , 2020, 220, 1230-1234.	1.8	3
16	Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 231, 434-447e2.	0.5	24
17	Premalignant Disorders of the Breast in Pregnancy and Lactation. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1252, 63-72.	1.6	1
18	Lobular Neoplasia. <i>Current Breast Cancer Reports</i> , 2020, 12, 36-43.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Research and Treatment, 2020, 180, 207-217.	2.5	17
20	Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. Annals of Surgical Oncology, 2019, 26, 4264-4271.	1.5	19
21	Developing a patient decision aid for women aged 70 and older with early stage, estrogen receptor positive, HER2 negative, breast cancer. Journal of Geriatric Oncology, 2019, 10, 980-986.	1.0	11
22	Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. Annals of Surgical Oncology, 2019, 26, 55-61.	1.5	36
23	Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clinical Breast Cancer, 2019, 19, 146-155.	2.4	3
24	Evaluating the risk of underlying malignancy in patients with pathologic nipple discharge. Breast Journal, 2018, 24, 624-627.	1.0	11
25	Non-classic LCIS Versus Classic LCIS Versus Atypical Hyperplasia: Should Management be the Same?. Current Surgery Reports, 2018, 6, 1.	0.9	2
26	Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER) Medicare Registry. Breast Cancer Research and Treatment, 2018, 169, 287-293.	2.5	8
27	How Do We Approach Benign Proliferative Lesions?. Current Oncology Reports, 2018, 20, 34.	4.0	9
28	Complex sclerosing lesions and radial sclerosing lesions on core needle biopsy: Low risk of carcinoma on excision in cases with clinical and imaging concordance. Breast Journal, 2018, 24, 133-138.	1.0	11
29	Molecular determinants of post-mastectomy breast cancer recurrence. Npj Breast Cancer, 2018, 4, 34.	5.2	9
30	The Potential Impact of AMAROS on the Management of the Axilla in Patients with Clinical T1-2N0 Breast Cancer Undergoing Primary Total Mastectomy. Annals of Surgical Oncology, 2018, 25, 2612-2619.	1.5	14
31	Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. Annals of Surgical Oncology, 2018, 25, 3548-3555.	1.5	17
32	Impact of residual nodal disease burden on sentinel node mapping and accuracy of intraoperative frozen section in node positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2018, 36, 584-584.	1.6	1
33	The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology, 2017, 24, 2563-2569.	1.5	26
34	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC) Tj ETQq0 0 0.0gBT /Overlock 10 T		
35	Papilloma on Core Biopsy: Excision vs. Observation. Annals of Surgical Oncology, 2015, 22, 1479-1482.	1.5	46
36	Metabolic characterization of inflammatory breast cancer (IBC) with baseline FDG-PET/CT: Relationship with histopathology, hormone receptor status, and pathologic response after neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2013, 31, 1105-1105.	1.6	14